Business Description
Shenzhen Neptunus Interlong Bio-Technique Co Ltd
SIC : 2834
ISIN : CNE100000775
Share Class Description:
HKSE:08329: H SharesTotal Employee Number:
1,382Compare
Compare
Traded in other countries / regions
08329.Hong Kong IPO Date
2005-09-12Description
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.2 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -1.83 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.48 | |||||
Beneish M-Score | -3.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.9 | |||||
3-Year FCF Growth Rate | 43.1 | |||||
3-Year Book Growth Rate | -10.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.72 | |||||
9-Day RSI | 51.15 | |||||
14-Day RSI | 49.17 | |||||
3-1 Month Momentum % | 8.08 | |||||
6-1 Month Momentum % | -28.19 | |||||
12-1 Month Momentum % | -30.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2 | |||||
Quick Ratio | 1.5 | |||||
Cash Ratio | 0.64 | |||||
Days Inventory | 93.94 | |||||
Days Sales Outstanding | 59.63 | |||||
Days Payable | 72.93 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 29.01 | |||||
Operating Margin % | -5.05 | |||||
Net Margin % | -5.62 | |||||
EBITDA Margin % | -5.91 | |||||
FCF Margin % | 9.46 | |||||
OCF Margin % | 10.55 | |||||
ROE % | -7.74 | |||||
ROA % | -4.8 | |||||
ROIC % | -6.93 | |||||
3-Year ROIIC % | 45.42 | |||||
ROC (Joel Greenblatt) % | -15.12 | |||||
ROCE % | -7.45 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 3.5 | |||||
Price-to-Owner-Earnings | 2.76 | |||||
PS Ratio | 0.17 | |||||
PB Ratio | 0.23 | |||||
Price-to-Tangible-Book | 0.29 | |||||
Price-to-Free-Cash-Flow | 1.81 | |||||
Price-to-Operating-Cash-Flow | 1.62 | |||||
EV-to-EBIT | -1.66 | |||||
EV-to-EBITDA | -1.72 | |||||
EV-to-Revenue | 0.1 | |||||
EV-to-FCF | 1.07 | |||||
Price-to-GF-Value | 0.75 | |||||
Price-to-Projected-FCF | 0.2 | |||||
Price-to-Median-PS-Value | 0.48 | |||||
| Price-to-Net-Current-Asset-Value | 0.62 | |||||
Earnings Yield (Greenblatt) % | -60.24 | |||||
FCF Yield % | 55.31 | |||||
Forward Rate of Return (Yacktman) % | 1.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shenzhen Neptunus Interlong Bio-Technique Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 1,030.468 | ||
| EPS (TTM) (HK$) | -0.034 | ||
| Beta | -0.056 | ||
| 3-Year Sharpe Ratio | 0.01 | ||
| 3-Year Sortino Ratio | 0.02 | ||
| Volatility % | 25.57 | ||
| 14-Day RSI | 49.17 | ||
| 14-Day ATR (HK$) | 0.007265 | ||
| 20-Day SMA (HK$) | 0.10655 | ||
| 12-1 Month Momentum % | -30.97 | ||
| 52-Week Range (HK$) | 0.089 - 0.177 | ||
| Shares Outstanding (Mil) | 1,678 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shenzhen Neptunus Interlong Bio-Technique Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shenzhen Neptunus Interlong Bio-Technique Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| HKD 0.005370 Cash Dividend | 2025-05-15 | 0.35 (+1.45%) | ||
| HKD 0.151330 Cash Dividend | 2025-05-15 | 0.35 (+1.45%) |
Show
Entries
Shenzhen Neptunus Interlong Bio-Technique Co Ltd Frequently Asked Questions
What is Shenzhen Neptunus Interlong Bio-Technique Co Ltd(HKSE:08329)'s stock price today?
The current price of HKSE:08329 is HK$0.11. The 52 week high of HKSE:08329 is HK$0.18 and 52 week low is HK$0.09.
When is next earnings date of Shenzhen Neptunus Interlong Bio-Technique Co Ltd(HKSE:08329)?
The next earnings date of Shenzhen Neptunus Interlong Bio-Technique Co Ltd(HKSE:08329) is .
Does Shenzhen Neptunus Interlong Bio-Technique Co Ltd(HKSE:08329) pay dividends? If so, how much?
Shenzhen Neptunus Interlong Bio-Technique Co Ltd(HKSE:08329) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers